In children, cutaneous PAN is frequently associated with streptococcal infections, and positive streptococcal serology is included in the diagnostic criteria. Diagnosis
No specific lab tests exist for diagnosing polyarteritis nodosa. Diagnosis is generally based on the physical examination and a few laboratory studies that help confirm the diagnosis:
CBC (may demonstrate an elevated white blood count)
ESR (elevated)
Perinuclear pattern of antineutrophil cytoplasmic antibodies (p-ANCA) - not associated with "classic" polyarteritis nodosa, but is present in a form of the disease affecting smaller blood vessels, known as microscopic polyangiitis or leukocytoclastic angiitis
Tissue biopsy (reveals inflammation in small arteries, called arteritis)
Elevated C-reactive proteinA patient is said to have polyarteritis nodosa if he or she has three of the 10 signs known as the 1990 American College of Rheumatology (ACR) criteria, when a radiographic or pathological diagnosis of vasculitis is made:

Weight loss greater than/equal to 4.5 kg
Livedo reticularis (a mottled purplish skin discoloration over the extremities or torso)
Testicular pain or tenderness (occasionally, a site biopsied for diagnosis)
Muscle pain, weakness, or leg tenderness
Nerve disease (either single or multiple)
Diastolic blood pressure greater than 90 mmHg (high blood pressure)
Elevated kidney blood tests (BUN greater than 40 mg/dL or creatinine greater than 1.5 mg/dL)
Hepatitis B (not C) virus tests positive (for surface antigen or antibody)
Arteriogram (angiogram) showing the arteries that are dilated (aneurysms) or constricted by the blood vessel inflammation
Biopsy of tissue showing the arteritis (typically inflamed arteries): The sural nerve is a frequent location for the biopsy.
Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist. References
External links
"Revefenacin". Drug Information Portal. U.S. National Library of Medicine.